Email this article Transport and toxicity of 5-fluorouracil, doxorubicin, and cyclophosphamide in in vitro placental barrier model based on BeWo b30 cells
- Authors: Knyazev E.N.1,2,3, Nikulin S.V.2,3, Khristichenko A.Y.2,4, Gerasimenko T.N.2, Kindeeva O.V.2,3, Petrov V.A.2,5, Belyakova G.A.6, Maltseva D.V.1,2
-
Affiliations:
- M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
- Scientific Research Center Bioclinicum
- Far Eastern Federal University
- D. Rogachev Federal Scientific and Clinical Center for Pediatric Hematology, Oncology, and Immunology
- Institute of Nanotechnology of Microelectronics, Russian Academy of Sciences
- I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation
- Issue: Vol 68, No 12 (2019)
- Pages: 2344-2349
- Section: Full Articles
- URL: https://journals.rcsi.science/1066-5285/article/view/243569
- DOI: https://doi.org/10.1007/s11172-019-2709-7
- ID: 243569
Cite item
Open Access
Access granted
Subscription Access
Abstract
An in vitro placental barrier model based on human choriocarcinoma BeWo b30 cell line was considered as a method of preclinical study of the transport and toxicity of antitumor agents and other organic compounds. Low permeabilities were found for 5-fluorouracil as an example of hydrophilic compound and for doxorubicin as an example of a lipophilic compound with a high degree of binding to proteins and DNA and a high permeability was found for cyclophosphamide as an example of lipophilic compound with a low degree of binding to proteins. Using impedance spectrometry and cell viability assessment via reduction of resazurin to resorufin, a pronounced cytotoxic effect of doxorubicin and good tolerance of 5-fluorouracil and cyclophosphamide by the cells were shown for drug concentrations equal to the maximum concentrations in the patients’ blood during the treatment of breast cancer.
About the authors
E. N. Knyazev
M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences; Scientific Research Center Bioclinicum; Far Eastern Federal University
Author for correspondence.
Email: e.knyazev@bioclinicum.com
Russian Federation, 16/10 ul. Miklukho-Maklaya, Moscow, 117997; Build. 85, 2ul. Ugreshskaya, Moscow, 115088; 8 ul. Sukhanova, Vladivostok, 690091
S. V. Nikulin
Scientific Research Center Bioclinicum; Far Eastern Federal University
Email: e.knyazev@bioclinicum.com
Russian Federation, Build. 85, 2ul. Ugreshskaya, Moscow, 115088; 8 ul. Sukhanova, Vladivostok, 690091
A. Yu. Khristichenko
Scientific Research Center Bioclinicum; D. Rogachev Federal Scientific and Clinical Center for Pediatric Hematology, Oncology, and Immunology
Email: e.knyazev@bioclinicum.com
Russian Federation, Build. 85, 2ul. Ugreshskaya, Moscow, 115088; 1 ul. Samory Machela, Moscow, 117997
T. N. Gerasimenko
Scientific Research Center Bioclinicum
Email: e.knyazev@bioclinicum.com
Russian Federation, Build. 85, 2ul. Ugreshskaya, Moscow, 115088
O. V. Kindeeva
Scientific Research Center Bioclinicum; Far Eastern Federal University
Email: e.knyazev@bioclinicum.com
Russian Federation, Build. 85, 2ul. Ugreshskaya, Moscow, 115088; 8 ul. Sukhanova, Vladivostok, 690091
V. A. Petrov
Scientific Research Center Bioclinicum; Institute of Nanotechnology of Microelectronics, Russian Academy of Sciences
Email: e.knyazev@bioclinicum.com
Russian Federation, Build. 85, 2ul. Ugreshskaya, Moscow, 115088; 32A Leninsky prosp., Moscow, 119991
G. A. Belyakova
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation
Email: e.knyazev@bioclinicum.com
Russian Federation, Build. 2, 8 Trubetskaya ul., Moscow, 119991
D. V. Maltseva
M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences; Scientific Research Center Bioclinicum
Email: e.knyazev@bioclinicum.com
Russian Federation, 16/10 ul. Miklukho-Maklaya, Moscow, 117997; Build. 85, 2ul. Ugreshskaya, Moscow, 115088
